JP2023527542A5 - - Google Patents
Info
- Publication number
- JP2023527542A5 JP2023527542A5 JP2022573247A JP2022573247A JP2023527542A5 JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5 JP 2022573247 A JP2022573247 A JP 2022573247A JP 2022573247 A JP2022573247 A JP 2022573247A JP 2023527542 A5 JP2023527542 A5 JP 2023527542A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- ldl
- hefh
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063032451P | 2020-05-29 | 2020-05-29 | |
| US63/032,451 | 2020-05-29 | ||
| PCT/US2021/034489 WO2021243002A1 (en) | 2020-05-29 | 2021-05-27 | Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527542A JP2023527542A (ja) | 2023-06-29 |
| JP2023527542A5 true JP2023527542A5 (https=) | 2024-06-03 |
Family
ID=78722769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022573247A Pending JP2023527542A (ja) | 2020-05-29 | 2021-05-27 | コレステロール関連障害を治療するためのｐｃｓｋ９阻害剤及びその使用の方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230235085A1 (https=) |
| EP (1) | EP4157887A4 (https=) |
| JP (1) | JP2023527542A (https=) |
| CN (1) | CN115916838A (https=) |
| AR (1) | AR122180A1 (https=) |
| AU (1) | AU2021281256A1 (https=) |
| CA (1) | CA3179316A1 (https=) |
| IL (1) | IL298375A (https=) |
| JO (1) | JOP20220322A1 (https=) |
| TW (1) | TW202210524A (https=) |
| WO (1) | WO2021243002A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| BR112021013807A2 (pt) | 2019-01-18 | 2021-11-30 | Astrazeneca Ab | Inibidores de pcsk9 e seus métodos de uso |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| AU2024324802A1 (en) | 2023-08-14 | 2026-03-05 | Salubris (Chengdu) Biotech Co., Ltd. | Method for treating or preventing cholesterol-related diseases using pcsk9 inhibitor |
| WO2025265012A1 (en) * | 2024-06-21 | 2025-12-26 | Amgen Inc. | Compositions comprising anti-pcsk9 antbodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| KR20230074283A (ko) * | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
-
2021
- 2021-05-27 CA CA3179316A patent/CA3179316A1/en active Pending
- 2021-05-27 AU AU2021281256A patent/AU2021281256A1/en active Pending
- 2021-05-27 AR ARP210101427A patent/AR122180A1/es unknown
- 2021-05-27 CN CN202180039317.4A patent/CN115916838A/zh active Pending
- 2021-05-27 EP EP21812361.0A patent/EP4157887A4/en active Pending
- 2021-05-27 JP JP2022573247A patent/JP2023527542A/ja active Pending
- 2021-05-27 WO PCT/US2021/034489 patent/WO2021243002A1/en not_active Ceased
- 2021-05-27 IL IL298375A patent/IL298375A/en unknown
- 2021-05-27 US US17/999,373 patent/US20230235085A1/en active Pending
- 2021-05-28 TW TW110119435A patent/TW202210524A/zh unknown
-
2022
- 2022-11-27 JO JOJO/P/2022/0322A patent/JOP20220322A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023527542A5 (https=) | ||
| Saunders et al. | Triple therapy in early active rheumatoid arthritis: a randomized, single‐blind, controlled trial comparing step‐up and parallel treatment strategies | |
| Fischer et al. | Efficacy of cineole in patients suffering from acute bronchitis: a placebo-controlled double-blind trial | |
| JP2020002171A5 (https=) | ||
| JP2013521303A5 (https=) | ||
| JP2020500152A5 (https=) | ||
| Fei et al. | Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study | |
| JP2015526458A5 (https=) | ||
| WO2017064615A1 (en) | Use of c5 inhibitors in transplant associated microangiopathy | |
| EP2582373A1 (en) | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation | |
| JP2020502261A5 (https=) | ||
| AU2015315628A1 (en) | Use of reslizumab to treat moderate to severe eosinophilic asthma | |
| JP2022529929A5 (https=) | ||
| JP2021532176A5 (https=) | ||
| Alfano et al. | Awaiting a cure for COVID-19: therapeutic approach in patients with different severity levels of COVID-19 | |
| WO2022090169A1 (en) | Method of safe administration of anti-tau antibody | |
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| CN115702023A (zh) | 化脓性汗腺炎的治疗 | |
| JP2025501239A5 (https=) | ||
| TWI850365B (zh) | 治療克隆氏症(crohn's disease)的方法 | |
| JP2023544620A5 (https=) | ||
| Konstantinou et al. | Paradoxical worsening of chronic spontaneous Urticaria following Omalizumab administration: the missing link | |
| WO2023088436A1 (zh) | 抗pd-1抗体和抗vegf-a抗体的药物组合及其使用方法 | |
| RU2019108441A (ru) | Режим дозирования | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 |